Skip to content
Review Open access

Beyond Tacrolimus: Towards Personalized Immunosuppression in Heart Transplantation

Sep 2026 · Journal of Cardiac Failure · Vol 32, pp. 1594 - 1604 · 0 citations · 69 references
Medicine

TL;DR

Realizing the potential of personalized immunosuppression in heart transplantation will require not only a broader suite of validated biomarkers and integrative risk scores, but also novel pragmatic trial designs and surrogate endpoints to support the development of next-generation therapeutics.

Abstract

Heart transplantation remains the definitive treatment for end-stage heart failure and contemporary immunosuppressive regimens, typically a calcineurin inhibitor, antiproliferative agent, and corticosteroids, are applied with minimal pre-emptive individualization, despite profound heterogeneity in recipient immune biology, pharmacokinetics, comorbidity burden, and alloimmune risk. This review examines the case for personalized immunosuppression in heart transplantation across four domains. First, we survey the current landscape of immunosuppression, identify key gaps and discuss emerging strategies. Second, we review the evolving toolbox of post-transplant immune monitoring and molecular biomarkers, including donor-specific antibodies, gene expression profiling, donor-derived cell-free DNA, including technologies in development, appraising their clinical evidence, performance characteristics, and limitations. Third, we propose a framework for integrating existing tools into composite risk assessment and for developing new approaches to individualized patient management. Finally, we outline future directions for the field including pre-implantation graft gene editing, AI-assisted donor-recipient matching, and continuous risk assessment. Realizing the potential of personalized immunosuppression in heart transplantation will require not only a broader suite of validated biomarkers and integrative risk scores, but also novel pragmatic trial designs and surrogate endpoints to support the development of next-generation therapeutics.

Read PDF

Similar papers

Review Open access Sep 2026

From rejection to vasculopathy: a review of non-invasive biomarkers in alloimmune responses in heart transplantation

Non-invasive biomarkers have meaningfully advanced rejection surveillance in heart transplantation and hold promise for reducing procedural burden on patients, however, their role in detecting and monitoring CAV remains underdeveloped, and represents the most critical unmet need in the field.

Paula Majó Ribera, Lucy Bates, William E. Scott et al. · 0 citations
Review Open access Aug 2026

The new era of treatments for kidney transplant recipients

Key Points Unmet medical needs in kidney transplantation Increasing access to transplantation for highly sensitized patients. Development of selective lymphocyte-depleting induction therapies that favor a tolerogenic immunological environment following homeostatic reconstitution. Promotion of faster and more complete r...

H. Silva · 0 citations
Review Sep 2026

Extracorporeal Photopheresis in Heart Transplantation: From Salvage Therapy to Immunosuppression-Sparing Strategy.

Heart transplantation remains the definitive therapy for end-stage heart failure, yet graft survival continues to be limited by acute and chronic rejection and the cumulative toxicity of lifelong immunosuppression. Extracorporeal photopheresis (ECP), an immunomodulatory therapy with established efficacy in graft-versus...

A. Nathan, Francisco Arabia, J. Mahar · 0 citations
#gene editing Review Open access Sep 2026

Advances in Hematopoietic Stem Cell Transplantation: A Review of Recent Developments and Challenges

This review synthesizes contemporary breakthroughs in HSCT biology, technology, and clinical application, critically examines unresolved barriers, and highlights future directions, including Artificial Intelligence (AI)-driven predictive analytics, universal donor platforms, and equitable global access strategies.

M. Abah, Ovwigho Ugbede, O. C. et al. · 0 citations
Review Open access Aug 2026

Sequential antibody induction for immune tolerance in clinical organ transplantation: a feasibility review of immunosuppressant withdrawal protocols

This review systematically examines the immunological rationale and major clinical strategies (T-cell depletion, costimulation blockade, mixed chimerism, and regulatory cell therapy) and proposes four novel sequential regimens with explicit evidence levels based on efficacy, safety, and feasibility.

Ya-Chao Li, Fu-Xia Chen, Xia He et al. · 0 citations
Review Sep 2026

Immunosuppression in vascularized composite allotransplantation.

Tacrolimus-based triple therapy remains the clinical standard, with its concomitant nephrotoxicity requiring kidney transplantation after face and hand transplantation in some cases.

Davide Schilirò, Sofiu Ogunbiyi, L. Cendales · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.